X-inactive specific transcript (XIST) can determine sex differences in cardiovascular drug responses: focus on RNA...

Area of Science:

• Genetics
• Epigenetics
• Cardiovascular Science

Background:

• Sex differences in cardiovascular disease (CVD) prevalence and progression are influenced by genetic, hormonal, anatomical, and environmental factors.
• The female genome's two X chromosomes necessitate X chromosome inactivation, an epigenetic process for gene dosage control.
• Long non-coding RNA XIST plays a role in X chromosome inactivation and post-transcriptional gene regulation, potentially influencing autoimmune responses.

Purpose of the Study:

• To investigate the role of XIST in sex differences in cardiovascular drug responses.
• To propose XIST as a potential target for drug development, particularly for RNA therapeutics.
• To establish criteria for evaluating RNA therapeutics for cardiovascular disease in women.

Main Methods:

• Extensive literature analysis on genetic, hormonal, and epigenetic factors in CVD.
• Review of XIST's function in gene regulation and its potential as a drug target.
• Postulation of a hypothesis linking XIST to sex-specific cardiovascular drug responses.

Main Results:

• XIST's multifaceted roles suggest its involvement in sex-based variations in therapeutic efficacy.
• XIST emerges as a potential target for novel RNA therapeutics aimed at genetic and cardiovascular conditions.
• The study highlights the need for sex-specific considerations in drug development.

Conclusions:

• XIST may be a key determinant of sex differences in cardiovascular drug responses.
• Developing RNA therapeutics with XIST as a target or considering its off-target effects is crucial.
• Implementing specific criteria for RNA therapeutics development in women could mitigate adverse effects.